Legislative Activity

The "Medical Device Electronic Labeling Act" amends the Federal Food, Drug, and Cosmetic Act, permitting manufacturers to provide device labeling electronically, provided it is easily accessible. Paper copies must be available upon request without charge, and the device label itself must still comply with current regulations. The Secretary can implement additional requirements or exceptions for electronic labeling to ensure device safety and effectiveness.

The "Protecting Life from Chemical Abortions Act" restricts the Department of Health and Human Services and the FDA, requiring them to enforce Risk Evaluation and Mitigation Strategy (REMS) requirements for abortion drugs, reinstate the in-person dispensing requirement, and prohibits reducing REMS protections until standardized abortion data is collected by the CDC from every state. It also defines key terms such as "abortion," "abortion drug," and "unborn child" and prohibits the HHS secretary from declaring a public health emergency with respect to abortion.

This bill aims to improve federal programs for the prevention, detection, and treatment of traumatic brain injuries (TBIs). It updates the Public Health Service Act to enhance TBI prevention and surveillance, extends grant programs to include high-risk populations and Tribal entities, and requires the CDC to make aggregated TBI data publicly available. Additionally, the bill mandates studies and reports on TBI's long-term effects and high-risk populations, ensuring continued support and research in this critical area through 2030.

The "Protecting Life in Foreign Assistance Act" restricts federal funds from being used by foreign and domestic organizations that perform or promote abortions, furnish abortion-related items, or support entities that do so. This includes barring funds for referrals, counseling, lobbying, and training related to abortions. The restrictions do not apply to abortions in cases of rape, incest, or when the mother's life is at risk.

This bill amends the Social Security Act to equalize the negotiation period for drug price negotiations under the Drug Price Negotiation Program. It changes the negotiation period for small-molecule drugs from 7 years to 11 years, matching the period already in place for biologic drugs. This adjustment aims to create parity in negotiation timelines between different types of medications, effective as if included in the original legislation.

The "Accelerating Kids Access to Care Act of 2025" streamlines the enrollment process for out-of-state healthcare providers in Medicaid and CHIP, ensuring children under 21 have access to care from eligible providers across state lines. By reducing administrative burdens and unnecessary screening requirements, the Act aims to improve healthcare access for children while maintaining necessary safeguards against fraud and abuse. Participating providers will be enrolled for a 5-year period, and the changes will take effect three years after the Act's enactment.

This bill prohibits the use of federal funds to implement or enforce the Food and Drug Administration's final rule regarding the regulation of laboratory developed tests as medical devices.

The ASSIST Act of 2025 amends Title 38 of the United States Code to clarify that medical services for veterans include medically necessary automobile adaptations. The clarification includes specific adaptations such as ramp and kneeling systems, raised doors or lowered floors, and wheelchair tiedowns. This ensures veterans receive comprehensive support for their transportation needs.

The "Death Tax Repeal Act" eliminates both estate and generation-skipping transfer taxes, effective from the date of enactment. It adjusts gift tax calculations by setting the lifetime gift exemption at $10,000,000, with inflation adjustments after 2011. The Act also includes transitional rules for applying certain sections of the Internal Revenue Code during the enactment year.

The DRIVE Act of 2025 ensures that veteran's mileage reimbursement rate for travel to VA facilities is at least equal to the federal employee rate. It mandates the VA to pay these allowances within 90 days of a complete claim submission. This act updates outdated language to reflect these changes, aiming to provide equitable and timely compensation for veterans' travel expenses.

The Supporting the Local Radio Freedom Act prevents Congress from imposing new performance fees on local radio stations for playing music. It emphasizes the mutually beneficial relationship between broadcasters and the recording industry, where radio provides free publicity that boosts music sales and supports artists. The act recognizes local radio's crucial role in communities by providing news, weather updates, and public service announcements. Ultimately, this bill aims to protect local radio stations and businesses from economic harm, ensuring they can continue serving their communities without additional financial burdens.

The "Combating Illicit Xylazine Act" aims to combat the illegal use of xylazine by adding it to Schedule III of the Controlled Substances Act, which would allow for increased regulation and tracking of the substance. The bill includes exemptions and delayed effective dates for certain requirements to ease the transition for legitimate users, such as veterinarians and animal handlers. It also directs the Sentencing Commission to review sentencing guidelines for xylazine-related offenses and mandates reports to Congress on the prevalence and impact of illicit xylazine use. Finally, it will include xylazine in Arcos tracking.

The "National Right-to-Work Act" amends both the National Labor Relations Act and the Railway Labor Act to protect an employee's right to choose whether or not to join or support a labor union. It eliminates the possibility of mandatory union membership or dues payments as a condition of employment, ensuring that employees cannot be forced to join or support a union against their will.

The United States-Israel Defense Partnership Act of 2025 seeks to bolster the defense relationship between the United States and Israel through joint initiatives and increased cooperation. It establishes programs to counter unmanned systems, extend anti-tunnel and counter-UAS cooperation, and promote collaboration in emerging technologies like AI and cybersecurity. The act also mandates the establishment of a Defense Innovation Unit office in Israel and assesses integrated air and missile defense in the U.S. Central Command region. Finally, it explores Israel's potential inclusion in the national technology and industrial base.

The "Give Kids a Chance Act of 2025" aims to improve pediatric drug development and access by requiring more research into pediatric cancer drugs, ensuring completion of pediatric studies, and extending priority review vouchers for rare pediatric disease treatments. The act also addresses organ transplantation network improvements, limitations on orphan drug exclusivity, and establishes an FDA office to coordinate with Abraham Accords countries on regulatory standards. Additionally, the act allocates funding for pediatric drug studies and mandates reports and studies to assess the effectiveness of these changes.

The "Protecting Privacy in Purchases Act" prevents payment card networks from assigning a unique merchant category code to firearm retailers. The Attorney General is responsible for enforcing the Act, investigating complaints, and reporting to Congress. This law overrides state and local laws regarding merchant category codes for firearm retailers and does not establish a private right of action.

The "Protect Medicaid Act" prohibits federal Medicaid funding for state administrative costs associated with providing healthcare benefits to unauthorized immigrants. It requires a report from the Inspector General of the Department of Health and Human Services on how states that offer health benefits to non-lawfully admitted noncitizens handle Medicaid program administration costs separately. The report will also cover how these states fund programs for non-lawfully admitted noncitizens and analyze the impact of these non-lawfully admitted noncitizens receiving outpatient drugs purchased under the Medicaid Drug Rebate Program or the 340B drug discount program.

The "Health Care Provider Shortage Minimization Act of 2025" aims to address healthcare provider shortages by clarifying the tax status of qualified locum tenens physicians and advanced care practitioners. It ensures that these temporary healthcare providers are not classified as employees for tax purposes, provided they meet specific conditions such as working under a written contract and for no more than one continuous year at a service site. This clarification applies to services performed after the Act's enactment.

The "Diagnostics Testing Preparedness Plan Act of 2025" requires the Secretary of Health and Human Services to develop and regularly update a plan for the rapid development, validation, production, and distribution of diagnostic tests in response to public health emergencies. This plan aims to improve coordination between public and private entities, consider new technologies, address medical supply needs, and ensure efficient test distribution. The Secretary is authorized to contract with public and private entities to enhance domestic diagnostic testing capacity and must release the plan within one year, updating it every three years thereafter.

The "HALT Fentanyl Act" permanently classifies fentanyl-related substances as Schedule I drugs under the Controlled Substances Act, streamlining research registration processes while maintaining controls. It also updates penalties for trafficking, importing, and exporting fentanyl-related substances, treating them similarly to fentanyl analogues. Additionally, the Act addresses technical errors in previous legislation and mandates the Attorney General to issue rules for implementation.